US Capitol Capsule: Industry group vexed over FDA generics leadership void
This article was originally published in Scrip
Executive Summary
With the latest chief of the US FDA's Office of Generic Drugs (OGD), Dr Greg Geba, packing his bags on 15 March and leaving the agency after only eight months on the job, the head of the generics lobbying group last week voiced concern the departure could bring disruption and distraction, resulting in the flow of information and guidance to manufacturers being blunted, with drug approvals ultimately slowed.